|
1
|
Julia VT, Carsten N, Kater AP, Bahlo J, Fürstenau M, Fink AM, Gregor M, Thornton P, Tadmor T, Fischer K, Ritgen M, Kreuzer KA, Eldering E, Stilgenbauer S, Van Oers M, Geisler C, Hallek MJ, Eichhorst B. The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.tps7582] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Von Tresckow Julia
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
| | - Niemann Carsten
- Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Nordic CLL Study Group, Copenhagen, Denmark
| | - Arnon P. Kater
- Department of Hematology, Academic Medical Center Amsterdam, University of Amsterdam, on behalf of the HOVON CLL Working Group, Amsterdam, Netherlands
| | - Jasmin Bahlo
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Colgne, Germany
| | - Moritz Fürstenau
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
| | - Anna-Maria Fink
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
| | - Michael Gregor
- Division of Hematology. Cantonal Hospital of Lucerne, Lucerne, Switzerland, on behalf of the SAKK, Lucerne, Switzerland
| | | | - Tamar Tadmor
- Bnai–Zion Medical Center, on behalf of the Israeli CLL Study Group, Haifa, IL
| | - Kirsten Fischer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
| | - Matthias Ritgen
- 2nd Department of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Karl A Kreuzer
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
| | - Eric Eldering
- Department of Hematology, Academic Medical Center, on behalf of the HOVON CLL Working Group, Amsterdam, Netherlands
| | | | - Marinus Van Oers
- Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands, on behalf of the HOVON CLL Working Group, Amsterdam, Netherlands
| | - Christian Geisler
- Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Nordic CLL Study Group, Copenhagen, Denmark
| | - Michael J. Hallek
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, CECAD Cluster of Excellence at the University of Cologne, Clinical Research Unit (KFO) 286, German CLL Study Group, University of Cologne, Cologne, Germany
| | - Barbara Eichhorst
- Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
| |
Collapse
|
|
2
|
Van Oers M, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Davis J, Stefanelli T, Banerjee H, Hoever P, Geisler C. Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.7517] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Marinus Van Oers
- Department of Hematology, Academic Medical Center, Amsterdam, the Netherlands, on behalf of the HOVON CLL Working Group, Amsterdam, Netherlands
| | - Lukas Smolej
- FN Hradec Kralove, Hradec Kralove, Czech Republic
| | - Mario Petrini
- Haematology Department, University of Pisa, Pisa, Italy
| | | | - Sebastian Grosicki
- Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland
| | - Mark-David Levin
- Albert Schweitzer Ziekenhuis Dordrecht and HOVON, HOVON, Netherlands
| | - Jaclyn Davis
- Novartis Pharmaceutcial Corporation, East Hanover, NJ
| | | | - Hiya Banerjee
- Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | | | | |
Collapse
|